Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of two systematic review(s)/meta-analysis(es). ^[1-2]
• Lurbinectedin demonstrated improved overall survival in platinum-sensitive cell lung cancer (SCLC) compared to oral topotecan (hazard ratio (HR): 0.43; 95% CrI: 0.27, 0.67), IV (intravenous) topotecan (HR: 0.43; 95% CrI: 0.26, 0.70), and platinum re-challenge (HR: 0.42; 95% CrI: 0.30, 0.58).
• A systematic review involving 6349 patients assessed various treatments, including tyrosine kinase inhibitors (TKIs), topoisomerase I inhibitors, checkpoint inhibitors (CPIs), alkylating agents, and others. Promising phase 2 results were observed for TKIs and liposomal irinotecan, but no phase 3 data were available, and the clinical potential of CPIs and alkylating agents remains unclear.
• The effectiveness findings apply exclusively to platinum-sensitive SCLC patients, with no other subgroups or population types mentioned.
• Favorable Safety Profile in Platinum-Sensitive Patients: Lurbinectedin demonstrated a favorable safety profile compared to oral and IV topotecan, and platinum re-challenge in platinum-sensitive SCLC patients, with no specific adverse effects reported in the study.
• General Safety Concerns in Relapsed SCLC Treatments: 69% of reviewed publications reported low-/very-low-quality evidence due to issues such as lack of randomization and small sample sizes; specific adverse effects for lurbinectedin or other treatments were not provided.